Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TJO-002 (Xalost S) in Primary Open Angle Glaucoma or Ocular Hypertension
NCT03419975Phase 3Completed
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of latanoprost in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Taejoon Pharmaceutical Co., Ltd.. Started Apr 2016; status: completed.
02
Drugs
latanoprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03419975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419975.